Journal articleLancet Gastroenterol Hepatol2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
- Journal
- Lancet Gastroenterol Hepatol
- Published
- 14 January 2020
- Citations
- 180
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 5
- Builds on itPhase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC) NCT02301143↗
- BackgroundPrediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer NCT07226154↗
- BackgroundObservational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer NCT05379907↗
- BackgroundSequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With… NCT04570943↗
- BackgroundLaparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC NCT04855331↗